Since 1997, the molecular basis of six different types of Congenital Disorders of Glycosylation with a defect in the synthesis of N-glycans (CDG-I) has been identified. To assure an efficient molecular diagnosis of the six genes involved in these types, we established a denaturing high-pressure liquid chromatography (DHPLC) screening procedure. Primers were designed and conditions were optimised for the analysis of each exon of the PMM2, MPI, ALG6, ALG3, DPM1 and MPDU1 genes. Forty previously described PMM2 mutations were tested to evaluate the method. All of them could be detected. Hence, the sensitivity of the technique is virtually 100%. Screening of 17 novel cases with a tentative, clinical diagnosis of CDG-Ia identified mutations on both alleles in 14 of them, thereby confirming the diagnosis. Six of these mutations were not previously reported (G15E, G42R, Y64C, E93A, G214S and D223N). Sequencing of the complete coding sequence of PMM2 in the remaining three patients did not reveal mutations, corroborating the good performance of the DHPLC method. A similar DHPLC approach was also applied to CDG-Ib, CDG-Ic, CDG-Id, CDG-Ie and CDG-If samples. New mutations were identified in MPI (Y129C) and ALG6 (G227E). All results were confirmed by sequencing. We conclude that the DHPLC platform is a sensitive and efficient method for the rapid analysis of disease genes with a limited number of exons.
Introduction
In less than 5 years, the molecular defects of six types of congenital disorders of glycosylation, group I (CDG-I) have been identified (for review 1, 2 ). In CDG-I, patients have a deficiency in one of the enzymes involved in the synthesis or transfer of the dolichol-linked oligosaccharide precursor. 1 This results in a typical pattern of transferrin isoelectric focusing. The clinical diversity of CDG is remarkable, even within each group. 2, 3 CDG-Ia patients with a deficiency of phosphomannomutase (PMM) are the most frequent and have been extensively studied at the clinical, biochemical and molecular level (for instance 4 -6 ). The phenotype ranges from a severe multi-system disease including cerebellar hypoplasia, hypotonia, ataxia, psychomotor retardation, failure to thrive, and liver disease to a very mild phenotype with only mild mental retardation. 3, 7 The second most frequent type, CDG-Ic, has a clinical presentation that is close to, but typically milder than CDG-Ia. 8 -10 CDG-Ib has a different presentation, as it does not generally include neurological problems. 11 -13 The other types are rare. 14 -18 Confirmation of the clinical diagnosis relies on enzymatic studies and/or lipid-linked oligosaccharide (LLO) analysis followed by molecular analysis of the gene. 2 Most of the mutations described today are scattered over the corresponding genes. It seems that no hotspots exist be it that some mutations are more frequent, due to founder effects. 5, 6 For PMM2, more than 50 different mutations have been described. 6 Only six of them have been found in more than 10 families. In MPI and ALG6, 13 and 6 different mutations have been described in 10 and 9 patients respectively. 4, 10, 13, 19, 20 A survey of all published mutations in CDG-I can be found at http://www.kuleuven.ac.be/ med/cdg/.
The variety of mutations implicates that the whole coding region of the gene has to be examined for routine screening. In order to offer a fast screening of the six known genes and in anticipation of the identification of other genes involved in CDG-I, we introduced DHPLC analysis. DHPLC is a new screening method that allows the detection of single base variations based on the difference in melting profiles of hetero-and homoduplexes under controlled denaturing conditions. The method is automated and allows rapid screening of numerous samples in a 96-well format. The sensitivity has been shown to be 100% in several studies (for review see 21 ) and the platform has been implemented for screening of many disorders.
We designed primers and optimised the DHPLC procedure for all the exons of the PMM2, MPI, ALG6, ALG3, DPM1 and MPDU1 genes. The method has been used for routine diagnosis of 21 patients with tentative diagnosis of CDG-I and was found very convenient and sensitive.
Methods

Patients
Patients with known PMM2 mutations have previously been described. 7, 22 From 17 patients with a tentative diagnosis of CDG-Ia, nine had a phosphomannomutase deficiency in fibroblasts or leukocytes. From eight enzymatic data were not available but they all showed a type I transferrin IEF pattern and a clinical picture suggestive for CDG-Ia. Two patients were referred to our laboratory for molecular confirmation of CDG-Ib. In two novel patients with CDGIc, the clinical presentation, the transferrin IEF pattern and the accumulation of dolichol-Man 9 GlcNAc 2 , as shown by the analysis of lipid-linked oligosaccharides (LLO), 8 were suggestive for CDG-Ic. Total genomic DNA was extracted from blood, fibroblast cultures or EBV-transformed lymphoblast cultures by standard laboratory procedures.
PCR amplification
Primers have been designed for amplification of all individual exons of the six genes (PMM2, MPI, ALG6, ALG3, DPM1 and MPDU1), including at least 30 bp of intronic flanking region. Exons 4 and 5 of DPM1 and exons 2 and 3 of MPDU1 were amplified in one fragment. Primers were designed with 'Primer3' (http://www-genome.wi.mit.edu/ cgi-bin/primer/primer3_www.cgi) with a typical length of 20 bp. Primer sequences are available on request.
PCR reactions were done in 100 ml with 16PCR buffer (Roche, Mijdrecht, The Netherlands) with 25 pmol of each primer, 0.2 mM dNTP's, 2 U Taq polymerase and 200 ng genomic DNA. All PCR mixes were amplified with the same touch down program: 958C, 5 min, 10 cycles of (958C for 30 s, 658C (minus 18C/cycle) for 30 s, 728C for 30 s), 25 cycles of (958C for 30 s, 558C for 30 s, 728C for 30 s) and a final extension at 728C for 5 min.
PCR products were analysed on agarose and pooled prior to heteroduplex formation (958C for 2 min, slow cooling to 458C followed by 20 min at 458C). Amplicons of the same fragments from maximum three patients were pooled in approximately equal concentrations, as estimated from the intensity of the bands on agarose after EtBr staining.
DHPLC conditions
DHPLC analysis was performed on the Transgenomic Wave system as prescribed by the manufacturers (Transgenomic, Cheshire, UK). Ten ml of pooled (see above) crude PCR product (approximately 10 ng/ml) was loaded on a DNASep Column (Transgenomic). DNA was eluted from the column by a linear acetonitrile gradient in 0.1 mM triethylamine acetate (TEAA) buffer at a constant flow rate of 0.9 ml/ min. The gradient was formed by mixing buffer A (0.1 mM TEAA) and buffer B (0.1 mM TEAA, 25% v/v acetonitrile). The temperature of the oven for optimal heteroduplex separation at partial DNA denaturation was deduced from melting profiles of the DNA sequence, obtained with the Wavemaker 4.0 software (Transgenomic). Elution patterns of (pooled) patient samples were compared with those of normal control samples. Precise conditions (column temperature, gradient conditions) are available on request.
Identification of mutations by direct sequencing
Samples showing abnormal DHPLC profiles were reanalysed to confirm and identify the mutation. Fifty ml PCR product was purified on Microcon 100 columns (Millipore, Etten-Leur, the Netherlands). Direct sequencing was performed with the Big Dye Terminator cycle sequencing kit (Applied Biosystems, Foster City, CA, USA) essentially as described by the manufacturer. Samples were sequenced on an ABI 310 or ABI 3100 (Applied Biosystems) and analysed using the sequence analysis software of Applied Biosystems.
Results
Evaluation of the system
More than 50 different PMM2 mutations have been described in CDG-Ia patients and samples were available in our laboratory for most of these. Therefore, this gene was the perfect tool to optimise and evaluate the DHPLC analysis system. DNA samples of patients, known to be heterozygous for 40 different mutations were amplified and analysed at the proposed temperatures (Table 1) . Figure  1A gives an example of a melting profile, ie of exon 8, as generated by the Wavemaker software. The position of the eight mutated nucleotides in exon 8, included in this study, is indicated and so are the exon/intron boundaries. The elution profiles of a normal sample and of the eight mutant fragments at two column temperatures are shown in Figure  1B . In general, for 38 of the 40 mutations in this series, an elution profile clearly distinct from the control sample was DHPLC screening of six CDG-I genes E Schollen et al 644 obtained. The heteroduplexes with mutations V44A (exon 2) and I132T (exon 5) could not be visually separated from the wild type homoduplexes at the theoretical temperatures, calculated by Wavemaker 4.0. Only when the chromatograms of the mutant and normal control samples were overlaid, a difference could be detected (Figure 2 and results not shown). A screening at all temperatures from 508C (non denaturing conditions) to 628C (complete denaturation) did not result in a better separation.
I132T is caused by a T4C transition at position 395 in exon 5. A T4A transversion at the same position causes I132N. To check whether the specific base change itself affected the chromatogram, the elution profiles of fragments with I132T and with I132N were compared. The resolution of the peaks was much better for the fragment with the T4A transition than with the T4C transversion at the same position (Figure 2) , indicating that the precise nucleotide substitution strongly affects the melting characteristics of heteroduplexes, as expected.
Screening of PMM2 gene in CDG-Ia patients
The optimised conditions were used for routine screening of PMM2 in 17 patients with a possible diagnosis of CDGIa. The eight exons were amplified and PCR products were pooled prior to heteroduplex formation and analysis on DHPLC. Pooling warrants the identification of mutations in samples from patients that are homozygous for a particular mutation. Positive DHPLC patterns were further analysed by direct sequencing to confirm and identify the underlying mutation. Mutations were found on both alleles in 14 patients, confirming the diagnosis of CDG-Ia. Six mutations were not reported before: G15E, G42R, Y64C, E93A, G214S and D223N. Two other mutations (24delC, F206S) were published 6 before but not included in our test series. For the three other patients, the negative DHPLC results were confirmed by direct sequencing of the complete coding sequence and the flanking intronic sequences. The definitive diagnosis is pending in these cases.
Screening of MPI, ALG3, ALG6, DPM1 and MPDU1
The same strategy was followed for the other five genes. PCR primers and conditions were optimised for all exons. Known mutations were used to test the DHPLC conditions (column temperature and gradient). Table 3 lists the mutations in the different genes that were tested. All of them could easily be detected, although some problems have been encountered with MPI. The flanking regions of the several exons of MPI are very polymorphic and therefore obliterate the DHPLC read-outs. New primers were designed to circumvent this problem. In the last year two patients with CDG-Ib and two with CDG-Ic were referred to our centre for confirmation of the clinical diagnosis. All exons were analysed on DHPLC after amplification and heteroduplex formation. Fragments with an aberrant elution profile were sequenced. Two mutations were found and hence the diagnosis was confirmed for both CDG-Ic patients and for one of the CDG-Ib cases. Sequencing of the eight exons of MPI in the other CDG-Ib patient confirmed the negative DHPLC results. For both MPI and ALG6, a new mutation was identified: Y129C in MPI and G227E in ALG6.
Most recently, no novel patients have been diagnosed with CDG-Ib, Ic, Id, Ie and If in our service, and therefore, no diagnostic analyses were run for the corresponding genes. Still, the system is ready for use on patient material.
Discussion
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DHPLC screening of six CDG-I genes
DHPLC screening of six CDG-I genes E Schollen et al 646 protocols. We have not experienced any false negative results until now. Of course, this does not imply that all possible mutations will be detected after careful comparison of the chromatograms with a wild type sample, and some experience with the interpretation is an asset.
The only disturbance in the analysis stems from the presence of polymorphisms in the scrutinized fragments. For instance, two frequent polymorphisms in intron 5 of PMM2 (IVS5+19 C4T and IVS5+22 T4A) are detected by DHPLC using the primer sets and conditions, described in this study, and therefore complicate the analysis of exon 5. Because these polymorphisms are close to the splice site, they cannot be avoided by shuffling the primers without a loss of information. From a practical standpoint, because mutations in exon 5 are present on 60% of all mutant chromosomes, exon 5 has to be sequenced for most patients anyway. For MPI, new primers could be designed to avoid intronic polymorphisms.
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